AD Therapeutics
| Drug | Phase 3 clinical trial | Trial finding summary | Current FDA status |
|---|---|---|---|
| Aducanumab | EMERGE, ENGAGE, NCT02477800, NCT02484547 | Both halted at 50% enrollment on basis of futility analysis; EMERGE: Over 78 wk, average 22% slowing of cognitive decline in high-dose arm of study | Accelerated approval |
| Lecanemab | CLARITY-AD, NCT003887455 | Over 18 mo, average 25% slowing of cognitive decline | Approved |
| Donanemab | TRAILBLAZER-ALZ2, NCT04437511 | Over 18 mo, average 35% slowing of cognitive decline | Not approved; under consideration |